Medscape November 4, 2024
The US Food and Drug Administration (FDA) has cleared the Abbott Libre 2 and 3 continuous glucose monitoring (CGM) sensors for use during most imaging procedures, including MRI under certain specifications.
“Abbott rigorously tested its FreeStyle Libre 2 and 3 systems sensors to ensure they remain effective after radiologic procedures. This testing led the FDA to clear the removal of the contraindication requirement, with no changes made to the sensor,” the company said in a statement.
The sensors may also now be worn during CT or x-ray procedures. Previously, they were contraindicated for use during MRI, CT, and high-frequency electrical heat (diathermy) treatment due to concern that the exposure could potentially damage the sensor and lead to incorrect readings. Those...
Today's Sponsors
Today's Sponsor